Novel pyrimidinyl-diazospiro compounds

Abstract

The invention relates to Spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation.

1 . A compound of formula (I) which is 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt or solvate thereof. 
       
     
     
         2 . A compound as defined in  claim 1 , wherein the compound of formula (I) is a compound of formula (Ia): 
       
         
           
           
               
               
           
         
       
     
     
         3 . A compound of formula (I) as defined in  claim 1 , which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one hydrochloride (E1). 
     
     
         4 . A compound of formula (I) as defined in  claim 1 , which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one sulfuric acid salt (E2). 
     
     
         5 . A compound of formula (I) as defined in  claim 1 , which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one sulfuric acid salt hydrate (E3). 
     
     
         6 . A pharmaceutical composition comprising a compound of formula (I) as defined in  claim 1  or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 
     
     
         7 . (canceled) 
     
     
         8 . A method of treating a disease or condition mediated by modulation of voltage-gated sodium channels, comprising administering to a subject in need thereof a compound of formula (I) as defined in  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         9 . (canceled) 
     
     
         10 . A process for preparing a compound of formula (I) as defined in  claim 1 , which comprises:
 (a) forming a compound of formula (I) by performing a ring closure reaction of a compound of formula (II) followed by reduction of the resulting imine (IIA):   
       
         
           
           
               
               
           
         
         (b) deprotection of a protected derivative of a compound of formula (I); 
         (c) optional formation of a pharmaceutically acceptable salt of a compound of formula (I).